Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease

This Phase II, randomized, double-blind trial evaluated the efficacy and safety of inhaled liposomal amikacin, as compared with placebo, in 89 patients with treatment-refractory pulmonary non-tuberculous mycobacterial disease (Mycobacterium avium complex or Mycobacterium abscessus). The primary endpoint was change from baseline in mycobacterial growth scale; other endpoints included sputum conversion, 6MWD and adverse events.